In previous articles we have discussed the potential of nanotechnology enabled drug delivery systems such as those offered by Nanoviricides and Bind Therapeutics. One private company funded by the United States Department of Defense (USDOD), Nanotherapeutics, is targeting a broad range unique applications with their nanotechnology enabled drug delivery systems.
Little information seems to be available about privately held Florida company Nanotherapeutics and this may be due in part to the fact that they are working on some truly unique applications for the USDOD. Founded in 1999, Nanotherapeutics landed a massive Department of Defense contract in March of this year that could be worth as much as $360 million over 10 years to develop manufacturing processes for drugs to treat bioterrorism and radiological threats. The base contract was for $135.8 million and two years with options up to 10 years and $358.9 million. Just last month, the company held a ground breaking ceremony for a 165,000 square foot manufacturing and development center located on a 30-acre campus. The purpose of this development center is to enable faster and more effective development of medical countermeasures designed to protect military populations against chemical, biological, radiological and nuclear attacks and genetically engineered infectious diseases.
The company uses a nanometer-scale particle technology to make new drugs and to make existing drugs more effective, including oral, inhaled and injectable drugs, and topical gels and creams. The company is working on some truly unique and varied applications of their technology with a very imprssive pipeline: